Annual report observation 丨 19 pharmaceutical commercial enterprises have exceeded 10 billion in revenue and only 2 alternatives

Annual report observation 丨 19 pharmaceutical commercial enterprises have exceeded 10 billion in revenue and only 2 alternatives

Annual report observation ? 19 pharmaceutical commercial enterprises have exceeded 10 billion in revenue and only 2 alternatives
Up to now, the 2019 annual reports of 25 listed companies in the Tonghuashun Pharmaceutical business sector have been released.Among them, 19 companies have revenues of more than 10 billion US dollars, and Shanghai Pharmaceuticals has even exceeded 100 billion yuan.In the pharmaceutical business sector, Shanghai Pharmaceuticals has the most revenue in 2019, and the report has actually achieved revenues of up to 1865.6.6 billion, an annual increase of 17.27%; Kyushu pass with 994.The revenue of 9.7 billion US dollars ranked second; Sinopharm was the same, Sinopharm shares followed closely, with revenue of 520 respectively.460,000 yuan, 445.440,000 yuan.The sauna and nightnet inventory found that Shanghai Pharmaceuticals’ performance has been increasing year by year.From 2011 to 2019, Shanghai Pharmaceuticals’ operating revenue increased from 54.9 billion to 1865.6.6 billion yuan.However, the net profit growth rate was significantly slower than revenue. From 2011 to 2019, Shanghai Pharmaceuticals’ net profit increased from 20.4.2 billion increased to 40.8.1 billion yuan.Among them, the net profit attributable to shareholders of listed companies increased by 5 year-on-year in 2019.15%.Shanghai Pharmaceutical’s main business covers the pharmaceutical industry and pharmaceutical commerce (distribution and retail). It is a large pharmaceutical industry group and one of the four largest pharmaceutical distribution companies in the country. It has a direct network covering 24 provinces and cities in the country.Modern drug distribution system.In 2011, the company realized “A shares + H shares”.Shanghai Pharmaceuticals said in its 2019 annual report that the company actively participated in the selection of distributors of volume-purchased varieties and won the bid for the common name market share in the first 11 pilot cities.At the same time, the company actively promoted the second batch of procurement opportunities with volume expansion across the country to provide value-added services such as market access, stock warehousing and project promotion for winning bidders.In addition, the company also accelerated the domestic distribution network coverage through mergers and acquisitions, completed the acquisition of Sichuan Guojia Holdings, completed the provincial platform construction and network extension layout in Jiangsu, Heilongjiang, Jilin and other provinces.With the continuous merger and expansion of Shanghai Pharmaceuticals, the goodwill value of Shanghai Pharmaceuticals has increased from 29 in 2011.8.9 billion soared to 107.9 billion yuan.Among them, the impairment of goodwill accrued in 2019 is as high as 7.05 ppm, including provision for goodwill impairment for respective Vitaco, Gansu Tiansen and Big Global5.6.8 billion yuan, 3947.01 million yuan and 9725.710,000 yuan, which also led to the impairment of Shanghai Pharmaceutical Assets.8%.Large mergers and acquisitions also brought about a sharp rise in debt, and Shanghai Pharmaceutical ‘s asset-liability ratio rose from 45 in 2011.49% rose to 63 in 2019.96%, until 2019, the highest Shanghai medical debt is as high as 876.4 billion.In terms of net profit, only * ST Tiansheng and Ruikang Medical and Health have net profits of -2.2.3 billion, -9.2.8 billion yuan.In terms of the decrease in net profit, a total of 7 pharmaceutical commercial enterprises had a partial decrease in net profit. * ST Tiansheng ‘s net profit continued to increase the most, at -2615.11%; followed by Ruikang Medicine, Neptune Biotech, Kaikai Industrial, China Medicine, Huatong Medicine, Tongji Hall.Editor Yue Qingxiu proofreading Wang Xin drawing Li Shiyang